# Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

> **NCT06731478** · PHASE3 · RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 726 (estimated)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Cancer

## Interventions

- **DRUG:** Trastuzumab Deruxtecan
- **DRUG:** pembrolizumab
- **DRUG:** Trastuzumab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06731478
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-27
- **Primary completion:** 2028-06-01
- **Final completion:** 2030-02-01
- **Target enrollment:** 726 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06731478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06731478, "Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06731478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*